Navigation Links
Data From REMEDEE Trial Featuring OrbusNeich's Combo™ Dual Therapy Stent to be Presented in Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011

HONG KONG, Nov. 1, 2011 /PRNewswire/ -- OrbusNeich today announced that data from REMEDEE (Randomized Evaluation of an abluMinal sirolimus coatED bio-Engineered stEnt), a randomized clinical trial of the Combo Bio-engineered Sirolimus Eluting Stent (Combo Dual Therapy Stent), will be presented in the Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011 in San Francisco. The presentation entitled "REMEDEE: A Prospective, Randomized Trial of a Combination Bioabsorbalble Polymer-based Anti-CD34 Antibody Sirolimus-Eluting Stent vs. a Durable Polymer-based Paclitaxel-Eluting Stent" by Michael Haude, M.D., of Medical Clinic I at the Lukaskrankenhaus in Neuss, Germany, will take place at 11:10 a.m. PST on Nov. 11 in the main arena.

The REMEDEE trial was designed to demonstrate the safety and effectiveness of the Combo Dual Therapy Stent compared to the TAXUS® Liberte® paclitaxel-eluting stent in patients with symptomatic, ischemic heart disease due to a stenotic lesion located in a native coronary artery. This objective was measured in patients by a comparison of in-stent late lumen loss at nine months post-procedure. The trial included 183 patients at sites in Asia, Australia, Europe and South America.

On Thursday, Nov. 10, the Combo Dual Therapy Stent will be featured in a REMEDEE Breakfast Symposium titled "The New Combo Dual Therapy Stent." The symposium will be chaired by Martin B. Leon, M.D., and Alexandre Abizaid, M.D., and will take place at 7 a.m. PST in room 120. The symposium will provide an overview of the stent's underlying pro-healing technology, Genous, and the rationale of the REMEDEE study. Dr. Leon will introduce the new category of dual therapy stents, Roxana Mehran, M.D., will discuss the need for novel stents, Dr. Abizaid will describe the technology behind the Combo Dual Therapy Stent, and Michael Haude, M.D., will discuss the REMEDEE study design. Other presentations will include the OCT assessment of pro-healing stent coverage by Stephen W. L. Lee, M.D. Ulf Landmesser, M.D., and Mitchell W. Krucoff, M.D., will provide an overview about ongoing and relevant clinical investigations for the Combo Dual Therapy Stent.

Another presentation highlighting the Genous pro-healing stent technology is a talk entitled "A Prospective, Multicenter, Randomized Trial of the Early Healing of Four Types of Stents Assessed by Optical Coherence Tomography" by Ladislav Groch, M.D. This will take place at 7:45 p.m. PST on Tuesday, Nov. 8, in room 121.

About Combo Dual Therapy Stent

OrbusNeich's Combo Dual Therapy Stent is the only dual therapy stent that accelerates endothelial coverage and controls neointimal proliferation. The Combo Dual Therapy Stent combines the pro-healing technology used in the Genous™ Stent for rapid endothelial coverage with an abluminal sirolimus drug elution for the control of neointimal proliferation.

About Genous  

Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The Genous Stent, which has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug eluting stents and is supported by data from more than 6,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous Stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Stent, as well as other stents and balloons marketed under the names of Azule™, R stent, Scoreflex™, Sapphire™, Sapphire II and Sapphire NC. Development stage products include the Combo Dual Therapy Stent, the only dual therapy stent to both accelerate endothelial coverage and control neo-intimal proliferation through the combination of the Genous pro-healing technology with an abluminal sirolimus drug elution. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit

Follow OrbusNeich on Twitter at, and learn more about the company and the Genous technology on OrbusNeich's YouTube Channel:

Editor's Notes: OrbusNeich will display the Combo Dual Therapy Stent, the Genous Stent and other products at booth No. 1429 at TCT 2011. Product images are available on request.

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Conatus Pharmaceuticals Terminates Phase 2 Clinical Trial of CTS-1027
2. CTRI Confirms Leading Indian CRO Supports Majority of Hemophilia Trials in India
3. Industrial Biotechnology China News 1109 - Annual Subscription
4. Cardiac Dimensions Announces First Patient Treated in TITAN II Clinical Trial
5. Californias Industrial Biotechnology Workforce: Creating Jobs and Leading Innovation
6. Defense Witness In Second Hepatitis C Trial In Nevada, Dr. Arthur Reingold, Testimony on Plausible Cause for Contamination Impeached
7. Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
8. Circassias Hay Fever Treatment Improves Patients Allergy Symptoms in Phase II Clinical Trial
9. SanBio Announces Site Opening of Phase 1/2a Clinical Trial of Novel Cell Therapy in Stable Stroke Patients at University of Pittsburgh Medical Center
10. Roka Bioscience Initiates External Trial for AOAC Certification
11. Aperion Biologics Reaches Midpoint of Enrollment in Z-Lig™ Anterior Cruciate Ligament Reconstruction Medical Device Performance Trial
Post Your Comments:
(Date:11/24/2015)...  Clintrax Global, Inc., a worldwide provider of clinical research services ... that the company has set a new quarterly earnings record in ... growth posted for Q3 of 2014 to Q3 of 2015.   ... , with the establishment of an Asia-Pacific ... United Kingdom and Mexico , ...
(Date:11/24/2015)... ... 2015 , ... This fall, global software solutions leader SAP and AdVenture Capital ... and pitch their BIG ideas to improve health and wellness in their schools. , ... win the title of SAP's Teen Innovator, an all-expenses paid trip to Super Bowl ...
(Date:11/24/2015)... Massachusetts , November 24, 2015 SHPG ... will participate in the Piper Jaffray 27 th Annual Healthcare ... Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ... , Chief Financial Officer, will participate in the Piper Jaffray 27 ... , NY on Tuesday, December 1, 2015, at 8:30 a.m. ...
(Date:11/24/2015)... -- Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual General Meeting ... Israel time, at the law offices of ... th Floor, Tel Aviv, Israel . ... Izhak Tamir to the Board of Directors; , election of ... approval of an amendment to certain terms of options granted to our ...
Breaking Biology Technology:
(Date:11/18/2015)... New York , November 18, 2015 ... Market Research has published a new market report titled ... Growth, Trends, and Forecast, 2015 - 2021. According to the ... in 2014 and is anticipated to reach US$29.1 bn ... to 2021. North America ...
(Date:11/16/2015)... Calif. , Nov 16, 2015  Synaptics ... of human interface solutions, today announced expansion of ... TouchView ™ touch controller and display driver ... revolution of smartphones. These new TDDI products add ... TD4100 (HD resolution), TD4302 (WQHD resolution), and TD4322 ...
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
Breaking Biology News(10 mins):